Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475497 | 1.00 | USP2 (0.36) | USP2SLCO1B1PAX8LMNAL3MBTL1 | |
| SCHEMBL19295 | 0.94 | PAX8 (0.32) | PAX8 | |
| SCHEMBL166837 | 0.94 | PAX8 (0.32) | PAX8 | |
| SCHEMBL2704166 | 0.94 | PAX8 (0.32) | PAX8 | |
| Hydrazine SCHEMBL1326324 | 0.92 | PAX8 (0.31) | PAX8 | |
| Sulfuric Acid SCHEMBL9863900 | 0.92 | PAX8 (0.31) | PAX8 | |
| Hydrochloric Acid SCHEMBL5913921 | 0.92 | PAX8 (0.31) | PAX8 | |
| Hydrochloric Acid SCHEMBL1814659 | 0.90 | PAX8 (0.30) | PAX8 | |
| Hydrochloric Acid SCHEMBL6929597 | 0.90 | PAX8 (0.30) | PAX8 | |
| Hydrochloric Acid SCHEMBL1199579 | 0.90 | PAX8 (0.30) | PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173010-A1 | Polymetaphosphate based formulations for therapy of microcrystalline arthropathies | UNIVERSITÁ DEGLI STUDI DI SIENA (IT) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173010-A1 | Polymetaphosphate based formulations for therapy of microcrystalline arthropathies | PHOSPHO1, PMM2, SOST | USP2 4168/4885SLCO1B1 1111/4885PAX8 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.